Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors

Next Previous
Trial Profile

Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Acronyms COMPLETED
  • Sponsors Organon; Schering-Plough

Most Recent Events

  • 31 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 26 Jun 2009 Planned end date changed from 1 May 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
  • 27 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top